{
    "clinical_study": {
        "@rank": "158299", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with\n      acute respiratory distress syndrome.\n\n      II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients."
        }, 
        "brief_title": "Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis", 
        "condition": [
            "Sepsis", 
            "Respiratory Distress Syndrome", 
            "Respiratory Distress Syndrome, Adult"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult", 
                "Acute Lung Injury", 
                "Sepsis", 
                "Toxemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      This is a dose escalation study.\n\n      Patients receive vasoactive intestinal peptide (VIP) IV over either 6 or 12 hours.\n\n      Cohorts of 3 patients each receive escalating doses of VIP over either 6 or 12 hours until\n      the maximum tolerated dose is determined.\n\n      Patients are followed for 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Diagnosis of adult respiratory distress syndrome (ARDS) with sepsis\n\n        ARDS characterized by: hypoxemia refractory to supplemental oxygen therapy, diffuse\n        pulmonary infiltrates, no cardiogenic cause of pulmonary edema, and reduced pulmonary\n        compliance\n\n        Sepsis characterized by: Two or more of the following: Fever or hypothermia; Tachycardia;\n        Tachypnea; WBC greater than 12,000/mm3 or less than 4,000/mm3 or immature neutrophils;\n        Hypotension; Clinical suspicion of infection; Inadequate organ perfusion or organ\n        dysfunction as demonstrated by: Acute deterioration in mental acuity (excluding sedatives\n        or other nonsepsis causes) OR Unexplained metabolic acidosis OR Oliguria for greater than\n        2 hours OR Unexplained coagulopathy (elevated PT or PTT or platelet count decreased to\n        less than 50% of baseline within 24 hours or less than 100,000/mm3) OR Acute elevation of\n        bilirubin to greater than 2.0 mg/dL AND elevation of alkaline phosphatase, SGOT, or SGPT\n\n        No sepsis with unstable BP\n\n        --Prior/Concurrent Therapy--\n\n        At least 30 days since prior enrollment in investigational trial; No other concurrent\n        enrollment in investigational trial\n\n        --Patient Characteristics--\n\n        Hematopoietic: See Disease Characteristics; No uncontrolled hemorrhage (transfusion of 4\n        or more units required within past 24 hours); No chemotherapy induced neutropenia\n        (granulocyte count less than 1000/mm3)\n\n        Hepatic: No severe liver disease with portal hypertension\n\n        Renal: No anuria (urine output less than 50 mL/day)\n\n        Cardiovascular: No cardiogenic shock\n\n        Neurologic: No recent stroke, head trauma, or increased intracranial pressure; No other\n        serious neurologic disorder\n\n        Other: Not pregnant; No acquired immune deficiency syndrome; No immunosuppressed\n        transplant patients; No severe burns; No irreversible underlying condition with rapidly\n        fatal course; No marked obesity; No recent history of diarrhea"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004494", 
            "org_study_id": "199/14275", 
            "secondary_id": [
                "SUNY-SB-FDR001488", 
                "SUNY-SB-96-077", 
                "SUNY-SB-98-2606", 
                "FD-R-0001488"
            ]
        }, 
        "intervention": {
            "intervention_name": "vasoactive intestinal peptide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Vasoactive Intestinal Peptide"
        }, 
        "keyword": [
            "cardiovascular and respiratory diseases", 
            "immunologic disorders and infectious disorders", 
            "neonatal disorders", 
            "rare disease", 
            "respiratory distress syndrome", 
            "sepsis"
        ], 
        "lastchanged_date": "March 7, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Sami I. Said", 
                    "phone": "631-444-1754"
                }, 
                "facility": {
                    "address": {
                        "city": "Northport", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11768"
                    }, 
                    "name": "Veterans Affairs Medical Center - Northport"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sami I. Said", 
                    "phone": "631-444-1754"
                }, 
                "facility": {
                    "address": {
                        "city": "Stony Brook", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11790-7775"
                    }, 
                    "name": "State University of New York Health Sciences Center - Stony Brook"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "State University of New York", 
            "last_name": "Sami I. Said", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004494"
        }, 
        "source": "Stony Brook University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "State University of New York", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "FDA Office of Orphan Products Development", 
                    "agency_class": "U.S. Fed"
                }
            ], 
            "lead_sponsor": {
                "agency": "Stony Brook University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1999"
    }, 
    "geocoordinates": {
        "State University of New York Health Sciences Center - Stony Brook": "40.926 -73.141", 
        "Veterans Affairs Medical Center - Northport": "40.901 -73.343"
    }
}